3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
94
Leukemia
18
Leukemia, Myeloid, Chronic-Phase
14
Precursor Cell Lymphoblastic Leukemia-Lymphoma
11
Blast Crisis
8
Myeloproliferative Disorders
4
Leukemia, Myeloid
4
Bone Marrow Diseases
4
Recurrence
3
Philadelphia Chromosome
3
Leukemia, Myeloid, Accelerated Phase
3
Hematologic Diseases
3
Bronchiolitis Obliterans Syndrome
3
Hematologic Neoplasms
2
Piebaldism
1
Neoplastic Processes
1
Neoplasms by Histologic Type
1
Neoplasms
1
Neoplasm, Residual
1
Mastocytosis, Systemic
1
Leukemia, Myeloid, Acute
1
Hypereosinophilic Syndrome
1
Gastrointestinal Stromal Tumors
1
Interventions
nilotinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplastic Processes
×
nilotinib
×
Myeloid
×
Clear all
NCT01844765
2021-04-22
DIALOG
Novartis
Phase 2
Completed
59 enrolled
33 charts
1 FDA